Degruyter Revac Revac-2021-0136 220..252 ++

Total Page:16

File Type:pdf, Size:1020Kb

Degruyter Revac Revac-2021-0136 220..252 ++ Reviews in Analytical Chemistry 2021; 40: 220–252 Review Article Giovanni D’Orazio*, Chiara Fanali, Chiara Dal Bosco, Alessandra Gentili, and Salvatore Fanali* Chiral separation and analysis of antifungal drugs by chromatographic and electromigration techniques: Results achieved in 2010–2020 https://doi.org/10.1515/revac-2021-0136 received December 16, 2020; accepted May 25, 2021 1 Introduction Abstract: The determination and separation of enantio- Antifungal substances were discovered almost 80 years mers is an interesting and important topic of research in ago by D. W. Woolley. Since 1958, chlormidazole was the fi - various elds, e.g., biochemistry, food science, pharma first specific drug that was commercialized in medical - ceutical industry, environment, etc. Although these com practice for topical application [1]. pounds possess identical physicochemical properties, a Fungal infections have emerged in the past 40 years ff pair of enantiomers often has di erent pharmacological, and are becoming a major public health alarming dis- toxicological, and metabolic activities. For this reason, ease. The increasing rate of invasive fungal infections - chiral discrimination by using chromatographic and electro [2,3] is due to the increased incidence of the immune- migration techniques has become an urgent need in the compromised patient population, including the rising pharmaceutical field. This review intends to offer the number of acquired immunodeficiency for the advent of “state of the art” about the separation of chiral antifungal HIV, cancer patients with chemotherapy, organ trans- drugs and several related precursors by both liquid and plant recipients receiving immunosuppressive therapy, gas chromatography, as well as electromigration methods. on the one hand; the increasing number of invasive This overview is organized into two sections. The first one devices (catheters, artificial joints, and valves), on the describes general considerations on chiral antifungal drugs. other hand. The second part deals with the main analytical methods for The azoles compounds are important synthetic medi- the enantiomeric discrimination of these drugs, including a cinal products so named for the presence of an imidazole brief description of chiral selectors and stationary phases. or triazole moiety in the molecule. They are well-known Moreover, many recent applications attesting the great due to their quite extensive potent activities towards interest of analytical chemists in the field of enantiomeric many pathogenic fungi. In addition, some of them exhibit separation are presented. additional antibacterial and antiparasitic properties. Keywords: antifungal drugs, chiral separation, electro- Thealmostacceptedactionmodeofazolecompounds migration methods, nano-LC, HPLC, SFC relies on the inhibition of Lanosterol 14α-demethylase (CYP51A1), a key enzyme in the ergosterol biosynthesis. The latter is a fundamental component of the plasma mem- brane structure and its depletion causes a weakening of the membrane. This is related both to the consequent change in theactivityofmanymembrane-bound enzymes associated * Corresponding author: Giovanni D’Orazio, Istituto per i Sistemi with nutrient transport and chitin synthesis and to the Biologici (ISB), CNR – Consiglio Nazionale delle Ricerche, α- - Monterotondo, 00015 Rome, Italy, e-mail: [email protected] accumulation of toxic 14 methylated sterols in mem * Corresponding author: Salvatore Fanali, Teaching Committee of branes [4,5]. Ph.D. School in Natural Science and Engineering, University of A great part of active substances, belonging to imi- Verona, Verona, Italy, e-mail: [email protected] dazole and triazole derivatives, shows optical isomerism, - Chiara Fanali: Faculty of Science, University Campus Bio Medico of like more than half of drugs on the market [6]. Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy Chiara Dal Bosco, Alessandra Gentili: Department of Chemistry, The enantiomers of the same molecule have identical University of Rome “La Sapienza“, Piazzale Aldo Moro 5, P. O. Box physical and chemical properties in an achiral environ- 34, Posta 62, 0018 Roma, Italy ment (e.g., air–water exchange, abiotic absorption, and Open Access. © 2021 Giovanni D’Orazio et al., published by De Gruyter. This work is licensed under the Creative Commons Attribution 4.0 International License. Chiral separation of antifungal drugs 221 transformation), but they enantioselectively interact with organisms and they can act as biological markers of envir- biological systems, e.g., enzymes, proteins, receptors, onmental toxicity: for example, (2R,4S)-propiconazole and other chiral molecules [7]. In this frame, the pharma- exhibited 2.43–23.47-fold higher fungicidal activity toward cological activity may also be related to just one enantiomer, Rhizoctoniasolani,Fulviafulva,Alternariasonali,and being the other one inactive or even toxic. Consequently, Botrytis cinerea than (2S,4S)-propiconazole [16].Asimilar enantiomers may have different pharmacokinetic processes trend was observed for (2R,4S)-difenoconazole, whose fun- as well as therapeutic effects. gicidal activity against Botrytis cinerea is about 24.2 times Although antifungal drugs, such as imidazole and higher than that of its (2S,4S)-stereoisomer [15]. triazole derivatives, are present as racemic mixtures in Although a different effect of drug enantiomers in medicinal products, a lot of applications demonstrated pharmaceutical and agrochemical applications is demon- different biological effects of each enantiomer. For instance, strated, the racemic form is still currently available on a bacteriostatic test indicated that R-(−)-fenticonazole shows the markets of both medical products and plant treat- the minimum inhibitory concentration (MIC) of the anti- ments. Furthermore, it is estimated that about 50–75% fungal effects [8] and (+)-(S)-fenticonazole exhibited a faster of racemic pesticide emissions are unnecessary and cause absorption and elimination in female rats than did (−)-(R)- environmental pollution [17]. To reduce the risks of side fenticonazole [9]. Although the genaconazole is adminis- effects or unspecific toxicities derived from the adminis- tered as a racemate, only RR form is the active enantiomer tration of the no-active enantiomer, the new trend of the while SS-form is the inactive one. The concentration trend industrial sector is focused on the preparation of enantio- for a time in human serum does not show appreciable dif- merically pure compounds: in this way, the same effect ferences [10]. R enantiomer of azole compounds, such as would be produced by half the dose of the racemic form. fluconazole, genaconazole, itraconazole, posaconazole, In this frame, the development of analytical methodolo- ravuconazole, voriconazole, and sertaconazole, is two times gies for the chiral separation and determination of single- more active than the S-form, which is considered inactive enantiomer forms and their impurities is highly required. [11]; (−) enantiomer of ketokonazole is more potent against In doing this, pharmacokinetics and pharmacodynamics some strains of fungi [12] since, as demonstrated after studies (including absorption, distribution, metabolism, administration of rac-ketoconazole to rats, the concentra- and excretion) are needed, for both pharmaceutical and tion of (+)-ketoconazole in plasma was two-fold higher environmental (agrochemical) applications. The determi- than that of (−)-ketoconazole [13]. nation of a racemic antifungals in biological fluids of In recent years, due to their excellent antifungal humans or animals treated with one dose of drug can activity and a relatively low environmental persistence, be useful to investigate the dose/effect relationship during triazole fungicides have also become an important cate- a therapeutic drug monitoring (TDM): this information can gory of fungicides with wide applicability in agriculture. guide the physician in optimizing the appropriate dose. In this respect, this molecules family, considered as pes- Through studies of the enantioselective behavior of ticides, was introduced for the treatment and protection chiral pesticides in agri-food products or in the environ- of plants, such as cereals, soybeans, fruits, and vegeta- ment, the absorption, transformation, and degradation bles since the mid-1970s. processes in various plants, soil, water, and aquatic life As above reported, it is known that most of the tria- are generally also evaluated. Thus, a better knowledge zole fungicides/pesticides used as a pharmaceutical drug of individual degradation or toxicological data of each are chiral, like approximately 30% of anthropogenic enantiomer could reduce the amount of pesticide avoiding agrochemicals. Moreover, their optical isomers exhibit unnecessary stereoisomer and be useful to evaluate the different bioactivity, toxicity, and degradation in the environmental risk and food safety. environment. For instance, the R-enantiomer of dinico- This article reports an overview of both recent HPLC nazole and uniconazole shows stronger fungicidal activi- and CE (coveringtheliteraturesince2010) and an as ties, whereas the S-enantiomer has higher plant growth exhaustive as possible review of GC, SFC, and miniaturized regulating activity [14]; the degradation of the difenocona- liquid chromatographic applications for chiral separations zole stereoisomers also showed stereoselectivity in vegeta- of antimycotic drugs. The effect of chromatographic/electro- bles and soil [15]. phoretic experimental
Recommended publications
  • Butenafine Hydrochloride/Climbazole 529 to Be Reduced in Patients with Hepatic Impairment (See Profile Solution in Water Has a Ph of 8.0 to 9.0
    Butenafine Hydrochloride/Climbazole 529 to be reduced in patients with hepatic impairment (see Profile solution in water has a pH of 8.0 to 9.0. Protect from light. below). Chlormidazole hydrochloride is an imidazole antifungal used USP 31 (Ciclopirox Olamine). A white to slightly yellowish- topically as the hydrochloride in the treatment of fungal infec- white, crystalline powder. Slightly soluble in water; very soluble ◊ Reviews. tions of the skin. in alcohol and in dichloromethane; practically insoluble in cy- 1. Letscher-Bru V, Herbrecht R. Caspofungin: the first representa- For a discussion of the caution needed when using azole antifun- clohexane. pH of a 1% solution in water is between 8.0 and 9.0. tive of a new antifungal class. J Antimicrob Chemother 2003; 51: gals during pregnancy, see under Pregnancy in Precautions of Store in airtight containers at a temperature of 5° to 25°. Protect 513–21. Fluconazole, p.532. from light. 2. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445–57. Preparations Adverse Effects 3. Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362: Proprietary Preparations (details are given in Part 3) Irritation and pruritus have been reported after topical applica- 1142–51. Pol.: Unifungicid. tion of ciclopirox. 4. McCormack PL, Perry CM. Caspofungin: a review of its use in the treatment of fungal infections. Drugs 2005; 65: 2049–68. Multi-ingredient: Austria: Myco-Synalar; Pol.: Polfungicid; Switz.: Antimicrobial Action 5. Morris MI, Villmann M. Echinocandins in the management of Myco-Synalar†. Ciclopirox has a wide spectrum of antifungal activity. It inhibits invasive fungal infections, part 1.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Fungi P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come
    P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come Fungi P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come Fungi Biology and Applications Second Edition Editor Kevin Kavanagh Department of Biology National University of Ireland Maynooth Maynooth County Kildare Ireland A John Wiley & Sons, Ltd., Publication P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come This edition first published 2011 © 2011 by John Wiley & Sons, Ltd. Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered Office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial Offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/ wiley-blackwell. The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • I|||||III US005567716A United States Patent 19 11 Patent Number: 5,567,716 Della Valle Et Al
    I|||||III US005567716A United States Patent 19 11 Patent Number: 5,567,716 Della Valle et al. (45) Date of Patent: Oct. 22, 1996 54 TRANS AND CISTRAUMATIC ACID SALTS Chemical Abstracts, vol. 83, No. 3, Abstract No. 29, 1165, p. HAVING CICATRIZANT ACTIVITY 40, Jul 21, 1975. ASSOCIATED TO BACTERIOSTATIC, Nakayama et al, Bull Chem. Soc. Jpn. vol. 64, pp. 358-365 ANTIVIRAL, ANTIBIOTIC OR ANTIFUNGAL (1991). ACTIVITY Breslow et al., J. Am. Chem. Soc., vol. 103 (10) pp. 2905-2907 (1981). 75) Inventors: Francesco Della Valle; Silvana Zimmerman etal, Plant Physiol. (1979) 63,536-541, "Iden Lorenzi, both of Padova, Gabriele tification of Traumatin, A Wound Hormone, as Marcolongo, Carrara San Giorgio, all 12-oxo-Trans-10 Dodecenoic Acid'. of Italy English et al., J. Biol. Chem. vol. 121, No. 2, (1937), 791-799, "The Wound Hormones of Plants: I. Traumatin, 73 Assignee: Lifegroup S.p.A., Rome, Italy the Active Principle of the Bean Test'. Goldemberg, J. Soc. Cosmet. Chem., 28, (Nov. 1977), 21 Appl. No.: 155,153 667-679, “Reduction of Topical Irritation”. Miyamoto et al, J. Soc. Cosmet, Chem. Japan, vol. 22, No. 22 Filed: Nov. 19, 1993 4, (1989), 254-262, "Effects of Cosmetics Containing Bio 30 Foreign Application Priority Data active Substances on Skin'. Rodriguez-Bigas et al, Plastic and Reconstructive Surgery, Nov. 23, 1992 IT Italy ................................. MI92A2674 vol. 81, No. 3 (Mar. 1988), 386-389, “Comparative Evalu (51) Int. Cl." ......................... A61K 31/195; A61K 31/20 ation of Aloe Vera in the Management of Burn Wounds in 52 U.S. Cl. .......................... 514/332; 534/676; 534/773; Guinea Pigs'.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,198,800 B1 K0 (45) Date of Patent: Apr
    US007 198800B1 (12) United States Patent (10) Patent No.: US 7,198,800 B1 K0 (45) Date of Patent: Apr. 3, 2007 (54) COMPOSITIONS AND METHODS (56) References Cited (75) Inventor: Thomas Sai Ying Ko. 4 Licence Road, U.S. PATENT DOCUMENTS Belgrave South, Victoria, 3160 (AU) 3,987,000 A * 10/1976 Gleichenhagen et al. ... 523/111 Y re. - - - 5,041.287 A * 8/1991 Driggers et al. .............. 424,81 (73) Assignee: Thomas Sai Ying Ko, Beijing (CN) 5,632,727 A * 5/1997 Tipton et al. ................. 602/47 5,708,023 A * 1/1998 Modak et al. .... ... 514,494 (*) Notice: Subject to any disclaimer, the term of this 5,725.491 A * 3/1998 Tipton et al. ................. 602/43 patent is extended or adjusted under 35 6,183,770 B1* 2/2001 Muchin et al. ............. 424/448 U.S.C. 154(b) by 781 days. * cited by examiner (21) Appl. No.: 09/717,088 Primary Examiner Sreeni Padmanabhan Assistant Examiner Gina Yu (22) Filed: Nov. 22, 2000 (74) Attorney, Agent, or Firm—Sughrue Mion, PLLC (30) Foreign Application Priority Data (57) ABSTRACT Nov. 23, 1999 (AU) ..................................... PQ4190 Non-aerosol spray-on skin patch compositions as described (51) Int. Cl. comprising at least one Substantially water insoluble film A6DF 3/00 (2006.01) forming agent, at least one film plasticizer agent, at least one AOIN 55/00 (2006.01) water soluble compound, and at least one organic solvent, (52) U.S. Cl. ...................... 424/443; 424/447; 424/448: the composition forming a flexible, porous and physiologi 424/449; 424/78.35: 525/363; 514/887: 514/494; cally compatible skin patch when sprayed on to skin and 602/43; 602/47 allowed to dry.
    [Show full text]
  • Determination of Antimycotic Substances, Derivatives
    Chem.Anal. (Warsaw), 41,19 (1996) Determination ofAntimycotic Substances, Derivatives ofImidazole', by ,Gas Chromatographic Method by,E. KlJblin andT. Kanjewska DepartmentofChemicalAnalysis, Institute ofDrugResearch and Control, 00-725 Warszawa, Poland Key words: bifonazole, chlormidazole, econazole nitrate, isoconazole nitrate, metroni­ dazole, miconazole, tioconazole, gas chromatography Simple method for gas-chromatographic identification of 7, among 9 used, antimycotic compounds, derivatives of imidazole has been elaborated. The conditions have been e~tablished for quantitative determination of selected compounds of this group present insubstlnces and such pharmaceuticals as ointments and creams. The column, packed with UCW-98 on Chromosorb WAW, and flame-ionisation ,detector were used. The, statistical data indicate satisfactory precision of the method, both in the determination ofimidazole derivatives in substances and in preparations. Opracowano prost<\,m'etod€( identyfikacji za pomoc<\, chromatografii gazowej 7, sposr6d 9 stosowanych, zwi<\,zk6w przeciwgrzybiczych, pochodnych imidazolu. Ustalono wa­ runki oznaczania ilosciowego wybral1ych zwi<\,zk6w z tej grupy w substancjach i pieparatach farmaceutycznych - masciach i kremach. Zastosowano kolumn€( wypetnio­ n<\, UCW-98 Ila Chromosorbie WAWoraz detektor 'ptomieniowo-jonizacyjny.' Dane statystyczne wykazuj<\, dostateczn<\,precyzj€( metody,zar6wno przy oznaczaniu zwi<\,z­ k6w - pochodnych imidazolu, w sUbstancjach, jak i w preparatach. Imidazole (1,3-diazole)derivatives are used
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • Antifungals of the Azole Type
    RISK PROFILE Antifungals of the azole type This concerns azole type molecules used to eradicate or control fungi. They are used, or may potentially be used, for cosmetic purposes as defined in the European Commission database for cosmetic ingredients currently called CosIng. Date of reporting 24.11.201 4 This risk profile deviates in its format from other risk profiles in the series of pharmacological active substances as presented on the webpages of the Norwegian Food Safety Authority (NFSA). This is because the health risk arising because of use in cosmetics of these molecules mainly has to do with a potential worsening of the serious global problem of antimicrobial/antibiotic resistance/cross-resistance. The other risk profiles in this series concerns the toxicity of different cosmetics ingredients. The NSFA base this risk profile mainly on concerns expressed by the European Medicinal Agency (EMA) that on two occasions – in 2005 and 2011 - addressed the unfortunate use of azole type antifungals in cosmetics products. Also the NSFA observes that the same concern has been expressed by the Council of Europe in a publication as from 2008 concerning the use of Active ingredients in cosmetics. Over the years the Norwegian Medicinal Products Agency has strongly encouraged the NFSA forcefully to oppose any use of molecule in cosmetics that might potentially weaken the medicinal anti-fungus armamentarium against life threatening systemic fungal infections in people having a seriously compromised immune system. Over the years, also the European Commission has addressed this issue asking its scientific committee working in the field of cosmetic products - currently called the Scientific Committee on Consumer Safety (SCCS) - for advice.
    [Show full text]